Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06700915

A Clinical Trial to Assess the Efficacy and Tolerance of a Berberine-based Nutraceutical Formula to Aid Blood Sugar Regulation and Metabolism

This randomized, triple-blind, placebo-controlled study will evaluate the efficacy of Diaberine, a berberine-based nutraceutical, in aiding blood sugar regulation and metabolism in 80 participants over 24 weeks.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Santa Monica, California, 90404, United States

Location status: Recruiting

Location contact

Patrick Renner, MSc

CONTACT

[email protected]

424-245-0284

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female.
  • BMI: 27-35 kg/m2
  • HbA1c of 5.7%-6.4% (determined by prescreening blood test)
  • Be generally healthy
  • Willing to refrain from taking any products, prescription medications, or supplements that target blood sugar regulation or metabolism during the test period.
  • Willing to maintain their current diet, sleep schedule, and activity level for the duration of the study.

Exclusion criteria

  • Diagnosed with Type 2 diabetes mellitus (T2DM) and have been prescribed metformin, insulin, Sulfonylureas, Meglitinides, SGLT2 inhibitors and/or GLP-1 medications including the following prescription medications: Wegovy (semaglutide), Ozempic (semaglutide), Rybelsus (semaglutide), Saxenda (liraglutide), Victoza (liraglutide), Zepbound (bimagrumab), Byetta (exenatide), Bydureon (exenatide ER), Trulicity (dulaglutide), Adlyxin (lixisenatide)
  • Current use or past history of use within the last 2 months (8 weeks) of the following prescription medications: Beta-blockers Sectral (Acebutolol), Tenormin (Atenolol), Kerlone, Betoptic (Betaxolol), Zebeta (Bisoprolol), Coreg, Coreg CR (Carvedilol), Trandate, Normodyne (Labetalol), Lopressor, Toprol XL (Metoprolol), Corgard (Nadolol), Bystolic (Nebivolol), Levatol (Penbutolol), Visken (Pindolol), Inderal, Inderal LA, InnoPran XL (Propranolol). Thiazide diuretics Diuril (Chlorothiazide), Microzide (Hydrochlorothiazide), Thalitone, Hygroton (Chlorthalidone), Lozol (Indapamide), Zaroxolyn (Metolazone), Naturetin (Bendroflumethiazide), Enduron (Methyclothiazide). Corticosteroids Deltasone (Prednisone), Orapred, Prelone (Prednisolone), Medrol (Methylprednisolone), Qvar (Beclomethasone), Celestone (Betamethasone), Decadron (Dexamethasone), Cortef (Hydrocortisone), Kenalog (Triamcinolone). Immunosuppressants Tacrolimus (Prograf), Cyclosporine (Neoral), Sirolimus (Rapamune)
  • Women who are pregnant, breastfeeding, or trying to conceive.
  • Anyone unwilling or unable to follow the study protocol.
  • Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Is currently undergoing or planning to undergo any significant medical procedures in the next six months
  • Has had any major illness in the last three months.
  • A history of severe allergic reactions, including but not limited to any of the product's ingredients.
  • Heavy drinkers or drug users. A heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinks per week.
  • Impaired hepatic function.
  • Individuals taking prescription or over-the-counter medication, or herbal remedies that affect blood sugar regulation or metabolism.
  • Currently being treated for an infection with an antibiotic and/or antiviral prescription medication.

Treatment and study plan

Diaberine

Dietary Supplement

Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.

placebo capsule

Dietary Supplement

Participants will take one capsule three times daily, 15 minutes prior to meals, over a 24-week period.

Primary outcomes

  1. Blood Sugar Regulation

    Time frame: Baseline, Week 12, and Week 24

    Evaluation of the effect of Diaberine on blood sugar regulation as measured by changes in HbA1c

  2. Metabolism

    Time frame: Baseline, Week 12, and Week 24

    Evaluation of the effect of Diaberine on metabolism, as measured by changes in lipid panel levels.

Secondary outcomes

  1. Quality of Life change

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24; Weight: Baseline and Week 24

    Assessment of participant-reported quality of life via a questionnaire.

  2. Weight Change

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24; Weight: Baseline and Week 24

    Evaluation of changes in participant weight.

Study contacts

Contact information is provided by the study sponsor or research team.

Patrick Renner, MSc

CONTACT

[email protected]

4242450284

Sponsors and collaborators

Lead sponsor

Ultimate International, Inc.

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 22, 2024
Registry last updated
Dec 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.